12 employees
X-VAX is a biotech company committed to developing vaccines against pathogens acquired by mucosal infection such as herpes.
2015
$56M
from 4 investors over 4 rounds
X-Vax Technology, Inc. raised $56M on July 23, 2019
Investors: Founders Fund, Helicase Venture and Adjuvant Capital
X-Vax Technology, Inc. raised undisclosed on April 5, 2019
Investors: Thynk Capital